Johnson Matthey and Domainex collaborate to enhance discovery and development services

Johnson Matthey and Domainex Ltd. have announced a collaboration to provide integrated small-molecule pharmaceutical discovery and development services

Register for free to listen to this article
Listen with Speechify
0:00
5:00
WEST DEPTFORD, N.J. & CAMBRIDGE, U.K —Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, and Domainex Ltd., a small-molecule drug discovery company, have announced a collaboration to provide integrated small-molecule pharmaceutical discovery and development services.
 
The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the United Kingdom and beyond with effective, simplified, rapid and reduced-risk target-to-lead identification, optimization, safety/toxicology, preclinical and clinical API supply services.
 
Domainex is a leading provider of small-molecule drug discovery services that complement the preclinical to commercial range of services provided by Johnson Matthey Fine Chemicals’ Custom Pharma Solutions offering in Europe, the companies note. Through an integrated offering co-located in the Cambridge region, customers will be able to access Domainex’s target-to-lead identification and optimization capabilities, and will then be able to transfer their projects directly to Johnson Matthey, utilizing its Pharmorphix solid-state services for effective salt form and polymorph identification through to process development, scale-up and non-GMP toxicology manufacture. With all activities co-located in the Cambridge area, discovery and development time and risk can be greatly minimized.
 
“Johnson Matthey and Domainex have together recognized there is customer demand for simplified and effective drug discovery and development services. With our combined expertise and facilities based in Cambridge, we are now able to offer customers significant value through this joint service offering,” said Antoine Bordet, European managing director at Johnson Matthey Fine Chemicals.
 
“The transition from drug discovery and candidate nomination into polymorph screening, preclinical toxicology and Phase 1 clinical development is a critical phase in the drug development process,” added Tom Mander, chief operating officer of Domainex. “We’re bringing together the necessary complementary people, skills and facilities with Johnson Matthey so that together we can offer an integrated and simplified solution spanning pharmaceutical discovery through to clinical development.”


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue